US Prescription Drug Prices Post Largest Annual Decline in Decades

Key Takeaways:  

• The US prescription drug price index declined 0.8% in July 2026, according to federal data. The broader medical care commodities index fell 2.7% year over year.¹
• The Trump Administration has attributed part of the decline in prescription drug prices to its Most Favored Nation (MFP) pricing initiative and TrumpRx platform.^2,3
• Other possible contributors include Medicare-negotiated prices implemented under the Inflation Reduction Act, generic competition, patent expirations, and existing manufacturer discounts. Available evidence does not establish the relative contribution of each factor. The effect on individual patients may vary based on insurance coverage, medication, pharmacy, and access to alternative discounts or generic products.^4,5

Prescription drug prices in the US recorded a substantial decline in 2026, with the Trump administration crediting its drug-pricing initiatives for helping drive the decrease. However, independent health policy analyses indicate that questions remain about how much of the decline can be directly attributed to the administration’s policies and how consistently lower prices will translate into savings for individual patients.^1,4,5

The latest Consumer Price Index report from the BLS showed that prescription drug prices declined 0.8% in July 2026. Medical care commodities, a broader category that includes prescription and nonprescription drugs and medical equipment and supplies, declined 2.7% during the previous 12 months.¹

Administration Credits Most Favored Nation Strategy 

The White House has attributed declining prescription drug prices in part to its MFN initiative, which is designed to bring US drug prices closer to prices paid in comparable developed countries.²

The administration has reached agreements with pharmaceutical manufacturers as part of that strategy. Its Council of Economic Advisers estimated that MFN pricing commitments could generate approximately $529 billion in US savings over 10 years.²

The policy stems from a May 2025 executive order directing federal officials to establish MFN price targets and pursue mechanisms intended to reduce disparities between prescription drug prices in the US and other developed countries.³

TrumpRx represents another component of the administration’s drug-pricing approach. The platform directs consumers to discounted prices for selected prescription medications through manufacturer arrangements and other purchasing options.⁵

Independent Analyses Raise Questions About Attribution 

Although BLS data document falling prescription drug prices, the Consumer Price Index does not determine what policies or other market factors caused those changes.¹ Therefore, the data alone cannot establish how much of the decline resulted from MFN agreements, TrumpRx, or other factors affecting prescription drug markets. 

An analysis from STAT also raised questions about the administration’s projected MFN savings. Because details of agreements between the federal government and manufacturers have not been fully disclosed, independently evaluating their ultimate effect on US prescription drug spending remains difficult.⁴

The real-world value of TrumpRx may also vary according to patients’ insurance coverage, medications, and available alternatives. 

KFF found that TrumpRx may provide meaningful discounts for some consumers, particularly those paying cash for medications, but noted that patients with insurance may sometimes obtain lower prices through their health plan or manufacturer assistance programs.⁵ 

KFF also reported that generic alternatives were available for some medications offered through TrumpRx and could sometimes be purchased at lower prices through pharmacies or other discount programs.⁵ 

Implications for Managed Care 

For payers and managed care organizations, the evolving drug-pricing environment could have implications beyond patients’ pharmacy-counter costs. 

If MFN agreements ultimately reduce prices for high-cost branded therapies, health plans could experience lower pharmaceutical expenditures. However, the magnitude of those savings will depend on implementation, manufacturer agreements, utilization patterns, and how new pricing arrangements interact with existing insurance benefits.^2,4

The distinction among list prices, negotiated net prices, and patient out-of-pocket spending also remains important. A decline measured by the Consumer Price Index does not necessarily mean that every patient will experience a corresponding reduction in prescription drug spending.^1,5

For managed care decision-makers, continued evaluation of utilization, formulary effects, net drug costs, and patient cost sharing will therefore be necessary to determine whether national price trends translate into sustained affordability improvements. 

Looking Ahead 

Federal data show a notable decline in prescription drug prices in 2026, while MFN agreements and TrumpRx represent significant changes in federal drug-pricing policy.¹⁻³ Determining how much these initiatives contribute to sustained reductions—and how broadly those savings reach insured and uninsured patients—will require additional data as the policies are implemented.^4,5

References 

1. US Bureau of Labor Statistics. Consumer Price Index—July 2026. Published August 12, 2026. Accessed August 17, 2026. https://www.bls.gov/news.release/cpi.nr0.htm 
2. The White House. Savings from Most-Favored-Nation drug pricing policy. Published May 5, 2026. Accessed August 17, 2026. https://www.whitehouse.gov/research/2026/05/savings-from-most-favored-nation-drug-pricing-policy/ 
3. The White House. Delivering Most-Favored-Nation prescription drug pricing to American patients. Published May 12, 2025. Accessed August 17, 2026. https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/ 
4. Payne D. Administration report on most favored nation drug pricing raises new details—and questions. STAT. Published May 6, 2026. Accessed August 17, 2026. https://www.statnews.com/2026/05/06/most-favored-nation-drug-price-savings-estimated-529-billion/ 
5. Pestaina K, Long M, and Lo J. TrumpRx: What’s the value for customers? KFF. Published February 24, 2026. Accessed August 17, 2026. https://www.kff.org/patient-consumer-protections/trumprx-whats-the-value-for-customers/